𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

✍ Scribed by Chao, Y; Chan, W-K; Birkhofer, MJ; Hu, OY-P; Wang, S-S; Huang, Y-S; Liu, M; Whang-Peng, J; Chi, K-H; Lui, W-Y

Book ID
109837566
Publisher
Nature Publishing Group
Year
1998
Tongue
English
Weight
866 KB
Volume
78
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti